MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma

被引：0

作者：

Peled, Nir ^{[1
]}

Lu, Xinyuan ^{[2
]}

Greer, John ^{[2
]}

Wu, Wei ^{[2
]}

Choi, Peter ^{[3
]}

Berger, Alice ^{[3
]}

Hann, Byron ^{[2
]}

Meyerson, Matthew ^{[4
,5
]}

Collisson, Eric ^{[2
]}

机构：

[1] Rabin Med Ctr, Tel Aviv, Israel

[2] UCSF, San Francisco, CA USA

[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[4] Broad Inst Harvard & Mit, Dana Farber Canc Inst, Boston, MA USA

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

MET; Resistance; Targeted therapy; Mouse model;

D O I：

10.1016/j.jtho.2016.11.1323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.03b042

引用

页码：S961 / S961

页数：1

共 50 条

[21] Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation [J].

Jorge, Susan E. ;

Schulman, Sol ;

Freed, Jason A. ;

VanderLaan, Paul A. ;

Rangachari, Deepa ;

Kobayashi, Susumu S. ;

Huberman, Mark S. ;

Costa, Daniel B. .

LUNG CANCER, 2015, 90 (03) :369-374

[22] MET Exon 14 Skipping in Non-Small Cell Lung Cancer [J].

Heist, Rebecca S. ;

Shim, Hyo Sup ;

Gingipally, Shalini ;

Mino-Kenudson, Mari ;

Le, Long ;

Gainor, Justin F. ;

Zheng, Zongli ;

Aryee, Martin ;

Xia, Junfeng ;

Jia, Peilin ;

Jin, Hailing ;

Zhao, Zhongming ;

Pao, Gwilliam ;

Engelman, Jeffrey A. ;

Iafrate, A. John .

ONCOLOGIST, 2016, 21 (04) :481-486

[23] Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation A case report [J].

Tan, Xiang ;

Dai, Lei ;

Wang, Yongyong ;

Liang, Guanbiao ;

Yang, Nuo ;

Chen, Mingwu .

MEDICINE, 2017, 96 (47)

[24] MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations [J].

Wu, Y-L. ;

Yong, S. ;

Yao, Y. ;

Cheng-Zhi, Z. ;

Wu, L. ;

Zhao, J. ;

Hu, J. ;

Yin, Y. ;

Lei, Y. ;

Gao, X. ;

Tang, M. ;

Gupta, R. ;

Biswas, C. ;

Orfanos, P. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S651-S652

[25] The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping [J].

Salgia, Ravi ;

Sattler, Martin ;

Scheele, Juergen ;

Stroh, Christopher ;

Felip, Enriqueta .

CANCER TREATMENT REVIEWS, 2020, 87

[26] Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis [J].

Huy Gia Vuong ;

An Thi Nhat Ho ;

Altibi, Ahmed M. A. ;

Nakazawa, Tadao ;

Katoh, Ryohei ;

Kondo, Tetsuo .

LUNG CANCER, 2018, 123 :76-82

[27] EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma [J].

He, Mai ;

Capelletti, Marzia ;

Nafa, Khedoudja ;

Yun, Cai-Hong ;

Arcila, Maria E. ;

Miller, Vincent A. ;

Ginsberg, Michelle S. ;

Zhao, Binsheng ;

Kris, Mark G. ;

Eck, Michael J. ;

Jaenne, Pasi A. ;

Ladanyi, Marc ;

Oxnard, Geoffrey R. .

CLINICAL CANCER RESEARCH, 2012, 18 (06) :1790-1797

[28] The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation [J].

Rocco, Danilo ;

Della Gravara, Luigi ;

Palazzolo, Giovanni ;

Gridelli, Cesare .

CURRENT MEDICINAL CHEMISTRY, 2024, 31 (21) :3043-3056

[29] A profile on capmatinib in treating adult patients with metastatic NSCLC tumors with MET exon 14 skipping mutations [J].

Hida, Toyoaki .

EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01) :96-101

[30] The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable [J].

Reungwetwattana, Thanyanan ;

Liang, Ying ;

Zhu, Viola ;

Ou, Sai-Hong Ignatius .

LUNG CANCER, 2017, 103 :27-37

← 1 2 3 4 5 →